A Squaric acid dibutyl ester quadratic acid dibutyl ester, the dibutyl ester of 3,4,-dihydroxycyclobutene-1,2-dione, or SADBE has been studied for the treatment of alopecia areata. Place in a light-resistant amber glass container dropper bottle or applicator bottle with a glass dropper or glass rod. Store in refrigerator. Procedure for Use Weigh container with chemical as received.
Stir to dissolve material. The first treatment with the squaric acid will be given in the office after two weeks. Then your doctor will instruct you to apply the solution on the warts at home. It is advised to wear gloves while applying squaric acid. A Q-tip is used to apply the solution directly on to the warts.
The squaric acid evaporates leaving no residue. Initially it is applied 3 times a week preferably at night. After the first week the frequency is increased to 4 nights a week then to 5 nights a week. Do not increase the frequency if your child experiences itching or soreness at the application sites. The main aim of the treatment is to have mild redness for the medicine to work and get rid of the warts. However, 16 of 28 patients who received 2.
Thus, we analyzed time to next outbreak after the sensitization dose. Data from patients who never experienced a first outbreak following sensitization were censored on the last available follow-up date and Kaplan-Meier time-to-event curves were estimated and graphed Figure. The median time to event for the placebo group was 40 days vs more than days for the 2.
Aside from autosensitization dermatitis that occurred in 1 patient after being exposed to the SADBE sensitization dose for 24 hours, the only other adverse events noted were itching and redness at the sensitization site, which was seen in 13 patients who received 2. This study suggests that sensitization of patients with SADBE may be useful in preventing herpes simplex virus outbreaks.
Our initial hypothesis was that treatment of an active lesion would be necessary to achieve the appropriate immunologic response, but our results suggest this additional step may not be necessary for many patients.
Limitations of our study include small sample size, few recurrences of herpes labialis lesions after sensitization limiting subsequent in-person evaluation , relatively short follow-up time, and recall bias of patient-reported number of previous outbreaks per year for subject inclusion. Published Online: May 24, Author Contributions: Drs Palli and Horn had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Critical revision of the manuscript for important intellectual content: All authors. No other conflicts are reported. Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy Continue.
View Large Download. Trial Protocol. Management of recurrent oral herpes simplex infections. Google Scholar. Sarnoff DS. Treatment of recurrent herpes labialis. J Drugs Dermatol.
0コメント